|
Status |
Public on Jan 25, 2019 |
Title |
MM.1S_drug |
Sample type |
SRA |
|
|
Source name |
multiple myeloma
|
Organism |
Homo sapiens |
Characteristics |
tissue: peripheral blood cell type: B lymphoblast treatment: 72 h after OR-S1 treatment
|
Treatment protocol |
MM cells were treated with 1 μM OR-S1 for 72 h.
|
Growth protocol |
RPMI1640 supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was isolated using an RNeasy Mini Kit (Qiagen). Libraries were prepared for sequencing using standard Illumina protocols.
|
|
|
Library strategy |
RNA-Seq |
Library source |
transcriptomic |
Library selection |
cDNA |
Instrument model |
Illumina NextSeq 500 |
|
|
Data processing |
Avadis NGS Version 2.1 software was used for analysis. Sequenced reads were trimmed for adaptor sequence, and masked for low-complexity or low-quality sequence, then mapped to hg19 whole genome using Avadis NGS Version 2.1. Genome_build: hg19
|
|
|
Submission date |
Jan 25, 2018 |
Last update date |
Jan 25, 2019 |
Contact name |
Makoto Nakagawa |
E-mail(s) |
makoto.nakagawa@duke.edu
|
Organization name |
Duke University
|
Department |
Department of Orthopaedic Surgery
|
Street address |
308 Research Drive
|
City |
Durham |
State/province |
NC |
ZIP/Postal code |
27710 |
Country |
USA |
|
|
Platform ID |
GPL18573 |
Series (2) |
GSE109673 |
Dual inhibition of EZH1/2 depletes stem cells and over-activates WNT signaling in multiple myeloma [RNA-seq] |
GSE109675 |
Dual inhibition of EZH1/2 depletes stem cells and over-activates WNT signaling in multiple myeloma |
|
Relations |
BioSample |
SAMN08397416 |
SRA |
SRX3600905 |